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A 20-year (1985–2004) retrospective review of 39
patients with imported visceral leishmaniasis found that
tourism to Mediterranean countries and HIV infection were
associated with visceral leishmaniasis. Diagnosis was
often delayed. Treatment with liposomal amphotericin B
has improved prognosis. Visceral leishmaniasis should be
made a reportable disease.
Each year, 500,000 new cases of visceral leishmaniasis(VL) are reported worldwide. The number of cases and
endemic foci for VL have increased during the past 2
decades (1–4). These increases may be the result of
improved detection and surveillance methods, or they may
be actual increases in numbers, possibly driven by increas-
ing rates of HIV infection (5,6). VL is a well-recognized
but uncommon imported disease in the United Kingdom,
but it is not reportable, so information on its importation is
incomplete. Data for this report (e.g., date of confirmation
of infection, country where acquired, HIV status) were col-
lated and supplied by the Travel Health Surveillance
Section of the Health Protection Agency, Communicable
Disease and Surveillance Centre, United Kingdom.
The Study
UK patients with VL are often referred to the Hospital
for Tropical Diseases, London, for confirmation of diagno-
sis or treatment. We reviewed all cases of VL seen at this
hospital from 1985 through 2004. Thirty-nine patients
were identified from our hospital database and laboratory
records, representing 83% of cases reported in the United
Kingdom (Figure 1).
The mean age of these patients was 36 years (range
2–66 years); 4 patients were <15 years of age. The
male:female ratio was 2:1. Patients acquired visceral leish-
maniasis while in the following areas: 30 (76.9%) in
Mediterranean countries (13 in Spain, 9 in Italy, 4 in
Greece, 3 in Malta, 1 in Cyprus), 5 (12.8%) from Africa, 3
(7.7%) from Asia, and 1 (2.6%) from South America.
During the entire 20-year period, 55.5% of patients had
been tourists to these VL-endemic regions, and 44.5%
were immigrants or refugees, but after 2000, all patients
were tourists. One third of the patients were HIV-antibody
positive. Two patients had significant immunosuppression
from other causes: 1 from chronic lymphatic leukemia and
1 from immunosuppressive drugs received after kidney
transplantation.
Time from onset of symptoms to diagnosis was 1–11
months (mean 3 months). Diagnoses of VL were con-
firmed by >1 method: microscopic identification of
amastigotes in tissue aspirates; histologic examination of
biopsy material from bone marrow, liver, or spleen; sero-
logic analysis; and PCR for leishmania DNA (7).
Leishmania amastigotes were found in 32 bone marrow
aspirates, 3 liver biopsy specimens, 2 splenic aspirates, and
1 skin biopsy specimen. PCR to detect leishmania DNA
has been performed in this study since 1995 and was pos-
itive in 7 of 11 cases. It was the method of confirmatory
diagnosis for 1 patient (performed on a bone marrow aspi-
rate that had no visible amastigotes). Serum analysis for
leishmania antibodies was performed on samples from 33
patients; results were positive for all HIV-negative patients
and for 2 of 13 HIV-positive patients (Table 1).
Before 1995, treatment of leishmaniasis involved sev-
eral drugs, including sodium stibogluconate, paro-
momycin, meglumine antimoniate, and pentamidine. The
latter 2 were used for patients who received initial treat-
ment outside the United Kingdom; within the United
Kingdom, most (59%) patients were treated with sodium
stibogluconate. After 1995, liposomal amphotericin
became the drug of choice and was used in 14 (83%) of 17
patients. HIV status did not affect drug choice. 
Figure 2 shows the frequency of relapses with each
drug treatment in our cohort. Of the 13 patients who had a
relapse, 8 (53%) had HIV coinfection. Of the 13 who had
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Figure 1. Number of visceral leishmaniasis (VL) cases, United
Kingdom, 1985–2004 (data from Health Protection Agency).
HIV coinfection, 8 (62%) had a relapse, compared with 7
(27%) of the 26 HIV-negative patients who had a relapse.
Two patients had other risk factors for relapse: 1 had had a
kidney transplant, and the other had chronic active hepati-
tis B. Three patients who had relapses had no apparent risk
factors. Relapse occurred in 5 (33%) of 15 patients who
received sodium stibogluconate, compared with 1 (7%) of
14 who received liposomal amphotericin as their initial
drug. At first, relapsed patients were treated with a combi-
nation of sodium stibogluconate and allopurinol, which
was unsuccessful in contrast with its reported success in
Kenya, or with amphotericin deoxycholate (8). HIV-infect-
ed patients who had relapses received further treatment
with liposomal amphotericin, usually successful, but 2
became unresponsive to treatment. Miltefosine was used in
2 patients with HIV coinfection who had relapses, but
relapses recurred, 1 while the patient was still receiving the
drug (9). Since 2000, pentamidine prophylaxis has been
used in 3 immunocompromised patients.
Table 2 summarizes outcomes. The number of patients
in the final cure category excludes patients who had had a
relapse. The 2 patients who refused treatment had HIV
coinfection; 1 died. After 1995, the final cure rate
improved and fewer patients required retreatment. The 3
patients who died had advanced HIV disease; 1 had an
additional complication of liver failure secondary to hepa-
titis C cirrhosis.
Conclusions
The data from this cohort show that VL is imported into
the United Kingdom at a constant rate, particularly in adult
male tourists to the Mediterranean, and that during the past
20 years, HIV and VL had interacted strikingly. The
Mediterranean VL-endemic zone accounts for only a small
proportion of VL cases globally, but it is a popular holiday
destination for the British, and tourism is driving the epi-
demiology of the imported infection. In the past 5 years,
we have seen no immigrants or refugees with VL. The data
show that high rates of tourism to an area of low endemic-
ity for a parasitic disease can result in a substantial number
of imported cases.
One third of our patients were immunocompromised.
The highest rates of reported HIV coinfection worldwide
are from Europe, where 85% of the cases are from the
southwest; 71% of these are in intravenous drug users (2).
HIV/VL coinfection is a serious disease that has high death
rates, reflected by the 3 deaths in our cohort. These
patients had late-stage HIV disease and additional coexist-
ing conditions. HIV/VL-coinfected patients have higher
relapse rates and decreased life expectancy. Highly active
antiretroviral therapy for HIV is decreasing the numbers of
these coinfections and improving survival rates (10,11).
The mean time from symptom onset to diagnosis was 3
months. This delay resulted mainly from physicians’ fail-
ure to consider the diagnosis, although a few cases were
difficult to diagnose. For 2 patients, initial microscopic
examination of bone marrow biopsy results did not show
amastigotes; reinspection showed scarce amastigotes. For
another patient, serologic results by direct agglutination
were negative when performed early in the course of dis-
ease but positive when repeated. The low sensitivity of
serologic tests for HIV-infected patients in this cohort con-
firms that serologic tests cannot be relied on as a means of
excluding VL in HIV-infected patients.
Our cohort shows a rise and fall in the proportion of
cases of HIV/VL coinfection, starting in the early 1990s,
rising to a peak of 50% during 1993–1996, and then
decreasing, possibly because of greater use of highly
active antiretroviral therapy. Official UK data on VL are
incomplete and do not accurately reflect trends. VL
remains an imported disease in the United Kingdom and is
often associated with HIV infection. We suggest that a for-
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Figure 2. Initial drug treatment for patients with visceral leishmani-
asis and number of relapses.  Na stibo, stibogluconate; Meg, meg-
lumine antimoniate; Paro, paromomycin; Pent, pentamidine; Amb,
ambisome; Amp, amphotericin.
mal notification system for visceral leishmaniasis in the
United Kingdom, as elsewhere in Europe, would be bene-
ficial for monitoring trends and health planning (12). Our
data also show the importance of looking at rare imported
diseases over a long period so that emerging risk factors
can be identified. These data also highlight the usefulness
of having 1 center that deals with unusual infections,
where expertise in diagnosis and management can be built
up and maintained.
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